期刊
CLINICAL NUCLEAR MEDICINE
卷 47, 期 12, 页码 1116-1117出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/RLU.0000000000004389
关键词
statin; PET/CT; F-18-FDG; SAMS; myositis
资金
- GE Healthcare
- CHR d'Orleans
This case illustrates the possibility of increased muscular F-18-FDG uptake without myositis in patients with statin-associated muscle symptoms. Discontinuation of statin treatment for one week can reduce muscular uptake.
Statin-associated muscle symptoms are a frequent adverse effect of statin treatment and can lead to a statin-associated myopathy characterized by a significant serum creatine kinase increase. We report the case of an 80-year-old man who presented an increased muscular F-18-FDG uptake in a statin-associated muscle symptom without creatine kinase abnormality or inflammation. Statin treatment was discontinued for 6 hours, 3 days, and 7 days on consecutive follow-up examinations. The 1-week window clearly enhanced image quality. This case illustrates the possibility of diffuse muscular F-18-FDG uptake without myositis and the need for a minimal 1-week statin discontinuation to reduce muscular uptake.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据